Menu Search
Equities

IQVIA Holdings Inc

QTS:FRA

IQVIA Holdings Inc

Actions
  • Price (EUR)193.25
  • Today's Change5.15 / 2.74%
  • Shares traded25.00
  • 1 Year change+0.55%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.

  • Revenue in USD (TTM)15.32bn
  • Net income in USD1.41bn
  • Incorporated2016
  • Employees88.00k
  • Location
    IQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 636-5454
  • Websitehttps://ir.iqvia.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.